RFL News and Press, Rafael Holdings Inc. Class B From 08/06/21

Kahn Brothers’ 13F portfolio value increased from $646M to $698M this quarter. BP plc and Pfizer were increased, while decreasing Nam Tai Property and BlackBerry during the quarter. The portfolio continues to be very concentrated with the top five positions accounting for ~...

NEW YORK, NY / ACCESSWIRE / August 2, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Rafael Holdings, Inc. (NYSE:RFL) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties re...

CRANBURY, N.J., July 01, 2021 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced positive outcome from its preplanned interim futility analysis of ...

CRANBURY, N.J., June 30, 2021 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced that data on its lead compound, devimistat, has been selected fo...

CRANBURY, N.J., June 29, 2021 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today that the U.S. Food and Drug Administration (FDA) granted orphan ...

Sarah Silbiger/Getty Images News The FDA has granted Orphan Drug designation to devimistat, a candidate from Rafael Pharmaceuticals for liver and intrahepatic bile duct cancer The conditions are also known as biliary tract cancer, and  cholangiocarcinomas of the bile duct and gall b...

Rafael Holdings and Rafael Pharmaceuticals Management Presented at the Raymond James 2021 Human Health Innovation Conference on June 22, 2021 PR Newswire NEWARK, N.J. and CRANBURY N.J. , June 23, 2021 /PRNewswire/ -- Rafael Holdings, Inc., (NYSE: RFL) an...

Merger news and drug development moved some stocks in Monday's pre-market action. Raven (RAVN) and Rafael Holdings (RFL) advanced on merger deals. Meanwhile, MediciNova (MNOV) and Theravance Bio (TBPH) moved in opposite directions on the release of new clinical trial data.The return of travel...

Zhanna Hapanovich/iStock via Getty Images Rafael Holdings (RFL) has added ~7.4% in the premarket after announcing a merger agreement with Rafael Pharmaceuticals, a private-owned late-stage oncology company in which the former and its subsidiaries has a majority stake. The president ...

Rafael Holdings Announces Strategic Merger with Rafael Pharmaceuticals to Form a Focused Late-Stage Clinical Oncology Company Rafael Pharmaceuticals' lead asset, CPI-613® (devimistat), is in Phase 3 clinical trials in pancreatic cancer and relapsed or refractory acute myelo...